---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-010267"
form_type: "8-K"
ticker: "JSPR"
cik: "0001788028"
company_name: "Jasper Therapeutics, Inc."
filed_at: "2024-02-06T23:59:59+00:00"
generated_at: "2026-06-06T08:23:12.718664+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Jasper Therapeutics prices $50M underwritten offering of 3.9M shares at $12.95/share

## Summary
- Gross proceeds ~$50M from 3,900,000 shares of common stock at $12.95 per share.
- Net proceeds to fund clinical development of briquilimab in mast-cell diseases (CSU, CIndU) and general corporate purposes.
- Offering expected to close on or about Feb 8, 2024; underwriters include TD Cowen and Evercore ISI.
- Directors and executive officers subject to 90-day lock-up expiring May 7, 2024.

## SEC filing metadata
- accession: 0001213900-24-010267
- form_type: 8-K
- ticker: JSPR
- cik: 0001788028
- company_name: Jasper Therapeutics, Inc.
- filed_at: 2024-02-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1788028/000121390024010267/0001213900-24-010267-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1788028/000121390024010267/ea192943-8k_jasper.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-010267
- JSON: https://secwatch.observer/filing/0001213900-24-010267.json
- Plain text: https://secwatch.observer/filing/0001213900-24-010267.txt

## Key facts
- Material Agreements
  Jasper Therapeutics, Inc. entered into Underwriting Agreement with Cowen and Company, LLC and Evercore Group L.L.C. valued at Underwritten offering of 3,900,000 shares of voting common stock at $12.95 per share; gross proceeds (effective 2024-02-06).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Cowen and Company, LLC and Evercore Group L.L.C.
  - Value: Underwritten offering of 3,900,000 shares of voting common stock at $12.95 per share; gross proceeds
  - Effective: 2024-02-06
  source text: On February 6, 2024, Jasper Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cowen and Company, LLC and Evercore Group L.L.C., as the representatives of the several underwriters named therein (the “Underwriters”), relating to an underwritten offering (the “Offering”) of 3,900,000 shares of the Company’s voting common stock (“Common Stock”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1788028/000121390024010267/0001213900-24-010267-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.